Core Viewpoint - Chuaning Bio, a leading company in the domestic bio-fermentation technology sector, has extended the lock-up period for its pre-IPO shares held by its controlling shareholder, Sichuan Kelun Pharmaceutical, until December 27, 2026, to enhance investor confidence and stabilize the capital market [1] Group 1: Shareholder Commitment - The lock-up extension involves approximately 1.61 billion shares, accounting for 72.19% of the company's total share capital [1] - This commitment reflects the controlling shareholder's confidence in the company's future development and intrinsic value [1] Group 2: Production and Market Outlook - Chuaning Bio reported that its three major intermediates are operating at full capacity, although the overall shipment volume has decreased by about 8% year-on-year [2] - The company anticipates a potential recovery in market demand for penicillin products, with prices currently at historical lows, and expects a positive trend as the traditional peak season approaches [2] - The company has initiated a collaboration with Shanghai Jincheng Technology to leverage AI in enhancing production efficiency in bio-fermentation [2] Group 3: AI and Product Development - The AI virtual engineer has shown an average production increase of 3%-5% compared to the control group and can predict fermentation trends in real-time [3] - Revenue from synthetic biology products reached 48.8 million yuan in the first three quarters of 2025, with improved order conditions compared to the previous year [3] - The company expects significant revenue growth in synthetic biology products as production capacity increases and market expansion continues [3] Group 4: Management's Strategic Focus - The management plans to deepen technological innovation, optimize industrial layout, and enhance operational quality to reward shareholders' trust and support [4] - Chuaning Bio aims to become a significant innovative force in the global biotechnology sector, creating sustainable value for shareholders [4]

格隆汇12月16日丨川宁生物(301301.SZ)公布，收到四川科伦药业股份有限公司（下称"科伦药业"）及其 控制的成都科伦宁辉企业管理合伙企业（有限合伙）（下称"科伦宁辉"）（前两者以下统称"控股股 东"）分别出具的《关于自愿延长限售股份锁定期的承诺函》，控股股东基于对公司未来发展前景的信 心和对公司内在价值的认可，同时本着对中小股东负责的态度，以实际行动维护资本市场稳定和公司股 东利益，进一步促进公司持续、稳定、健康发展，增强投资者信心，自愿延长其所持有川宁生物的首次 公开发行前限售股份（下称"首发前限售股"）的锁定期。 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-040 伊犁川宁生物技术股份有限公司 关于控股股东追加承诺自愿延长股份限售期的公告 股东四川科伦药业股份有限公司和成都科伦宁辉企业管理合伙企业(有限 合伙)保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 伊犁川宁生物技术股份有限公司（以下简称"川宁生物"或"公司"）于 2025 年 12 月 16 日收到四川科伦药业股份有限公司（下称"科伦药业"）及其控制的 成都科伦宁辉企业管理合伙企业（有限合伙）（下称"科伦宁辉"）（前两者以下 统称"控股股东"）分别出具的《关于自愿延长限售股份锁定期的承诺函》，控股 股东基于对公司未来发展前景的信心和对公司内在价值的认可，同时本着对中小 股东负责的态度，以实际行动维护资本市场稳定和公司股东利益，进一步促进公 司持续、稳定、健康发展，增强投资者信心，自愿延长其所持有川宁生物的首次 公开发行前限售股份（下称"首发前限售股"）的锁定期。具体情况如下： 一、追加承诺股东基本情况介绍 （一）基本信息 1、科伦药业基 ...

Core Insights - Chuaning Bio, a leader in synthetic biology, won the "Top 50 New Quality Productivity Awards" at the 19th Listed Company Value Forum, reflecting its strong financial performance and innovative capabilities [2] Group 1: Company Overview - Chuaning Bio operates in the pharmaceutical manufacturing industry and is located in the core area of the Belt and Road Initiative [3] - The company focuses on a dual-driven strategy of "biological fermentation" and "synthetic biology," primarily engaged in the R&D and industrialization of biological fermentation technology and synthetic biology products [3] - Key products include thiocyanate erythromycin, 6-APA, potassium penicillin G, cephalosporin intermediates, ursodeoxycholic acid, and rosmarinic acid, with several products ranking among the top globally in production [3] Group 2: Financial Performance - As of the 2024 annual report, Chuaning Bio's net profit increased from approximately 110 million to 1.4 billion [4] - By June 2025, the company completed its third dividend distribution in its third year post-IPO, with a total dividend amount of 1.3 billion, fully covering the raised funds of 1.1 billion [4] Group 3: Product Development and Market Position - Chuaning Bio's synthetic biology products currently include rosmarinic acid, 5-hydroxytryptophan, ergothioneine, squalene, and inositol, with the star product ergothioneine already on the market [3] - The company is actively expanding its market presence, particularly in cosmetics and health products, while its synthetic biology base is still in the capacity ramp-up phase [3]

川宁生物（301301.SZ）12月11日在投资者互动平台表示，公司采用合成生物学技术生产肌醇，相较于 传统提取工艺，在菌种设计、发酵工艺等方面具备创新优势。目前该技术已实现产业化应用，具体成本 数据涉及商业机密，望您理解。肌醇作为公司合成生物学重点产品，已进入生产阶段。目前巩留合成生 物学基地处于产能爬坡期，具体产能数据及明年销量规划将根据市场订单情况动态调整。公司肌醇已获 得饲料添加剂许可证书，广泛应用于水产、禽畜饲料领域。基于商业保密原则及信息披露合规要求，具 体客户信息暂不便透露，敬请谅解。公司将持续推进合成生物学产业化进程，相关进展请关注公司法定 披露渠道。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：近期关注到中国维生素产业发展高层论坛，川宁生物 继续推出肌醇（维生素B8）。采用生物技术合成替代传统提取方式成本是否有大幅降低。肌醇作为饲 料添加剂，获得了国内外饲料许可。现目前肌醇的价格如何？公司产能如何？预计明年销量如何？肌醇 在水产，禽畜饲料中的应用相当广泛，与公司合作的企业有哪些？ ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：流感病毒蔓延，公司的抗生素对其有辅助治疗的作用 吗？ 川宁生物（301301.SZ）12月11日在投资者互动平台表示，尊敬的投资者，您好！公司作为抗生素中间 体生产企业，主要产品包括硫氰酸红霉素、头孢类中间体、青霉素中间体等，上述产品均用于合成抗菌 类药物。若流感患者出现细菌性并发症（如细菌性肺炎），临床医生可能根据实际情况使用抗生素类药 物进行辅助治疗。公司产品系上述抗生素药物的上游中间体。感谢您对公司的关注！ ...

Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, with a total of 5,507 enterprises reported as of January-October 2025, marking an increase of 451 enterprises compared to the previous year, representing a year-on-year growth of 8.92% [1] Group 2 - The report indicates that the number of industrial enterprises in Xinjiang has increased significantly, contributing to 1.05% of the national total [1] - The data referenced in the article is sourced from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] - The article mentions that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1]

Core Viewpoint - The company is actively responding to national policy directives aimed at enhancing the adaptability of consumer goods, particularly in the context of the aging population and the silver economy [1] Company Developments - The company has noted the implementation plan issued by six departments, including the Ministry of Industry and Information Technology, which emphasizes the need for the development and design of products catering to the elderly [1] - The company is leveraging its synthetic biology technology platform to develop products in the cosmetics and health supplement sectors, with successful industrial applications of products such as rosmarinic acid, 5-hydroxytryptophan, and ergothioneine [1] Financial Performance - For the period from January to September 2025, the company reported a revenue of 3.436 billion yuan, representing a year-on-year decline of 22.90% [1] - The company's net profit attributable to shareholders was 611 million yuan, reflecting a year-on-year decrease of 43.17% [1]

Core Concept - The emergence of the Frontier Deployment Engineer (FDE) model is crucial in bridging the gap between artificial intelligence (AI) technology and industrial needs, transforming AI from laboratory results into practical industrial tools [1][2][3] FDE Role and Functionality - FDEs are hybrid professionals who understand both technology and industry, capable of translating abstract algorithms into actionable solutions that address core industrial pain points [2][3] - The FDE model disrupts traditional technology implementation by defining technology based on industry-specific needs, enabling cross-domain capability reuse, and ensuring transparent deployment processes [3][4] FDR as a Complementary Role - The Frontier Deployment Researcher (FDR) plays a critical role in the continuous optimization of deployed technologies, focusing on dynamic iteration and ensuring that AI solutions remain aligned with evolving industrial requirements [4][5] - FDRs are responsible for addressing model adaptation issues post-deployment, ensuring that AI systems can adjust to changes in production scenarios [5][6] Collaborative Framework - The collaboration between FDEs and FDRs creates a feedback loop that enhances the efficiency of model iteration, reducing the typical iteration cycle from three months to one to two weeks [7][8] - FDRs leverage their experience to create reusable technology modules, facilitating rapid adaptation across different industrial applications [7][8] Impact on Industrial AI - The FDE-FDR model significantly improves the adaptability and efficiency of industrial AI, allowing for real-time co-creation and continuous evolution of AI solutions [9][10] - The implementation of this model has led to substantial improvements in operational metrics, such as increasing control precision from 88% to 97% in specific projects [9][10] Future Directions - The focus will be on deepening technology, expanding ecosystems, nurturing talent, and promoting global outreach, with an emphasis on creating a robust talent pool of FDEs and FDRs [12][13] - The establishment of training programs and initiatives aims to enhance the capabilities of professionals in the field, ensuring that the industrial AI landscape continues to evolve and adapt to new challenges [12][13]

Core Viewpoint - The company emphasizes that the recent shareholder reduction in holdings is a normal market behavior based on individual financial arrangements and market conditions, and it adheres to information disclosure regulations [1] Group 1: Shareholder Actions - The company states that the shareholder reduction is a voluntary decision and reflects normal market behavior [1] - The company will disclose changes in shareholder holdings in its periodic reports [1] Group 2: Business Strategy - The chairman and management are focused on the development of the core business, implementing a dual-driven strategy of "biological fermentation + synthetic biology" [1] - The company aims to enhance its core competitiveness through technological innovation and cost control [1] Group 3: Governance and Compliance - The company is committed to maintaining standardized operations and optimizing its governance structure [1] - It will fulfill its information disclosure obligations in accordance with regulatory requirements for any significant matters [1]